942920-55-0|Ethyl 4-bromo-1H-pyrrolo[2,3-b]pyridine-2-carboxylate| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 942920-55-0 ] Purity: 95% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 942920-55-0 ]

CAS No. :	942920-55-0
Formula :	C₁₀H₉BrN₂O₂
M.W :	269.10
SMILES Code :	O=C(C1=CC2=C(Br)C=CN=C2N1)OCC
MDL No. :	MFCD11518924
InChI Key :	VLZWUULVFAASBC-UHFFFAOYSA-N
Pubchem ID :	44608107

Safety of [ 942920-55-0 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H332-H335
Precautionary Statements:	P261-P280-P305+P351+P338

Computational Chemistry of [ 942920-55-0 ] Show Less

Physicochemical Properties

Num. heavy atoms	15
Num. arom. heavy atoms	9
Fraction Csp3	0.2
Num. rotatable bonds	3
Num. H-bond acceptors	3.0
Num. H-bond donors	1.0
Molar Refractivity	59.88
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	54.98 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	2.28
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	2.56
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	2.5
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	1.91
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	2.85
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	2.42

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-3.37
Solubility	0.116 mg/ml ; 0.000429 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-3.36
Solubility	0.117 mg/ml ; 0.000434 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-4.25
Solubility	0.0153 mg/ml ; 0.0000569 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Moderately soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	Yes
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-6.12 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	0.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<0.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	2.07

Application In Synthesis of [ 942920-55-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 942920-55-0 ]

[ 942920-55-0 ] Synthesis Path-Downstream 1~35

1
[ 942920-55-0 ]
[ 73183-34-3 ]
[ 945865-21-4 ]

Yield	Reaction Conditions	Operation in experiment
68%	With potassium acetate;(1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; In N,N-dimethyl-formamide; at 90℃; for 48h;	A mixture of <strong>[942920-55-0]ethyl 4-bromo-1H-pyrrolo[2,3-b]pyridine-2-carboxylate</strong> (1.0 g, 3.9 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-1,3,2-dioxaborolane (2.1 g, 7.8 mmol), KOAc (1.2 g, 11.7 mmol) and Pd(dppf)Cl2 (0.3 g, 0.4 mmol) in DMF (20 mL) was heated at 90 C. for 48 h under inert atmosphere. After cooling to rt, the reaction was quenched by aqueous NH4Cl. The resulting mixture was extracted with AcOEt. The organic layer was washed with brine, water, and dried over sodium sulfate. Concentration in vacuo gave the residue, which was purified by YAMAZEN Fast Flow Liquid Chromatography (silica gel, EtOAc:hexane=1:1) to give the desired product as a white solid (0.8 g, 68%). 1H NMR (400 MHz, DMSO-d6) ppm 1.33-1.37 (m, 15H), 4.37 (q, 2H, J=7.1 Hz), 7.29 (d, 1H, J=2.0 Hz), 7.40 (d, 1H, J=4.5 Hz), 8.44 (d, 1H, J=4.3 Hz), 12.55 (brs, 1H). MS (ESI): m/z 315 (M-1)-, 317 (M+1)+
68%	With potassium acetate;dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; In N,N-dimethyl-formamide; at 90℃; for 48h;	Ethyl 4-bromo-1 H-pyrrolo[2,3-6]pyridine-2-carboxylate (1.0 g, 3.9 mmol), 4l4,4',4',5,5,5',5'-octamethyl-2,2'-bi-1,3,2-dioxaborolane (2.1 g, 7.8 mmol), KOAc (1.2 g, 11.7 mmol) and Pd(dppf)CI2 (0.3 g, 0.4 mmol) in DMF (20 ml_) was heated at 90 0C for 48 h under inert atmosphere. After cooling to rt, the reaction was quenched with aqueous NH4CI. The resulting mixture was extracted with AcOEt. The organic layer was washed by water, brine, and dried over sodium sulfate. Concentration in vacuo gave the residue, which was purified by YAMAZEN Fast Flow Liquid Chromatography (silica gel, EtOAc.hexane , 1:1) to give the desired product as a white solid (0.8 g, 68 %). 1H NMR (400MHz, DMSO-d6) ppm 1.33- <n="98"/>1.37 (m, 15H), 4.37 (q, 2H, J = 7.1 Hz), 7.29 (d, 1 H1 J = 2.0 Hz), 7.40 (d, 1 H1 J = 4.5 Hz), 8.44 (d, 1 H, J = 4.3 Hz), 12.55 (brs, 1 H). LC/MS: m/z 315 (M-1 )-, 317 (M+1)+.

References: [1]Bioorganic and Medicinal Chemistry Letters,2008,vol. 18,p. 4610 - 4614.
[2]Patent: US2009/18156,2009,A1 .Location in patent: Page/Page column 19.
[3]Patent: WO2007/76423,2007,A2 .Location in patent: Page/Page column 96-97.

2
[ 287384-82-1 ]
[ 942920-55-0 ]

Yield	Reaction Conditions	Operation in experiment
77%		Step A: Ethyl 4-bromo-1 H-pyrrolor2,3-lpyridine-2-carboxylate; Ethyl 1 H-pyrrolo[2,3-]pyridine-2-carboxylate-7-oxide (1 g, 5 mmol), (prepared using methods disclosed in WO 2000/044753 see Example 6, Step C), was added to a suspension of tetramethylammonium bromide (1.2 g, 7.5 mmol) in N, N- dimethylformamide (50 ml_). The resulting mixture was cooled to 0 C and methanesulfonic anhydride (1.7 g, 10 mmol) was added portionwise. After being warmed up to room temperature and stirred for another 6 hours, the reaction mixture was poured into water (100 ml_). After neutralization with 50 % aqueous sodium hydroxide, the resulting solution was extracted with ethyl acetate, followed by washing the organic layer with brine and water. Concentration in vacuo gave the residue, which underwent SCX purification to afford the title compound as a pale yellow solid (1 g, 77 %). 1H NMR (400 MHz, DMSO-d6) ppm 1.35 (t, 3 H, J = 7.1 Hz), 4.36 (q, 2 H1 J = 7.1 Hz), 7.05 (d, 1 H, J = 2.0 Hz), 7.48 (d, 1 H1 J = 5.1 Hz), 8.28 (d, 1 H, J = 5.1 Hz), 12.95 (brs, 1 H).
77%	With tetramethylammonium bromide; Methanesulfonic anhydride; In N,N-dimethyl-formamide; at 0 - 20℃; for 6h;	Ethyl 1H-pyrrolo[2,3-b]pyridine-2-carboxylate 7-oxide (1.0 g, 5.0 mmol), which was prepared according to WO2000044753, was added to a suspension of tetramethylammonium bromide (1.2 g, 7.5 mmol) in DMF (50 mL). The resulting mixture was cooled to 0 C. and methanesulfonic anhydride (1.7 g, 10 mmol) was added portion wise. After being warmed up to rt and stirred for another 6 h, the reaction mixture was poured into water (100 mL). By neutralizing it with 50% aqueous sodium hydroxide, the resulting solution was extracted with AcOEt, followed by washing the organic layer with brine and water. Concentration in vacuo gave the residue, which underwent SCX purification to afford the desired compound as a pale yellow solid (1.0 g, 77%). 1H NMR (400 MHz, DMSO-d6) ppm 1.35 (t, 3H, J=7.1 Hz), 4.36 (q, 2H, J=7.1 Hz), 7.05 (d, 1H, J=2.0 Hz), 7.48 (d, 1H, J=5.1 Hz), 8.28 (d, 1H, J=5.1 Hz), 12.95 (brs, 1H). MS (ESI): m/z 269, 271 (M+1)+
77%	With tetrabutylammomium bromide; Methanesulfonic anhydride; In N,N-dimethyl-formamide; at 0 - 20℃; for 6h;	Ethyl 1H-pyrrolo[2,3-6]pyridine-2-carboxylate 7-oxide (1.0 g, 5.0 mmol), which was prepared according to WO2000044753, and tetramethylammonium bromide (1.2 g, 7.5 mmol) were added to DMF (50 iml_). The mixture was cooled to 0 0C and methanesulfonic anhydride (1.7 g, 10 mmol) was added portion wise. The resulting suspension was warmed up to rt and stirred for 6 h. The mixture was poured in water (100 ml_) and the solution was neutralized with 50 % aqueous NaOH. The resulting solution was extracted with AcOEt, and then, the organic layer was washed by water and brine. Concentration in vacuo gave the residue, which was purified by SCX cartridge to afford the desired compound as a pale yellow solid (1.0 g, 77%). 1H NMR (400MHz, DMSO-c/6) ppm 1.35 (t, 3H1 J = 7.1 Hz), 4.36 (q, 2H, J = 7.1 Hz), 7.05 (d, 1 H, J = 2.0 Hz), 7.48 (d, 1 H1 J = 5.1 Hz), 8.28 (d, 1 H, J = 5.1 Hz), 12.95 (brs, 1 H). LC/MS: m/z 269, 271 (M+1)+

61%

With tetramethylammonium bromide; Methanesulfonic anhydride; In chloroform; at 0 - 25℃; for 16h;

To a stirred solution of 2-(ethoxycarbonyl)-lH-pynOlo[2,3-b]pyridine 7-oxide (3.50 g, 17.0 mmol) and Me4NBr (3.92 g, 25.5 mmol) in CHCb (40 mL) at 0 C was added Ms20 (5.91 g, 34.0 mmol) in portions. The reaction mixture was allowed to warm to 25 C and stir for 16 h. A pale yellow suspension was formed. LCMS showed the reaction was completed. The mixture was concentrated under reduced pressure to give a residue. The residue and the above batch were combined and neutralized with cold 0.5 N aq NaHCCb (80 mL) and stirred for 0.5 hour and then filtered. The filter cake was further purified by washing with EtOAc/pentane (15 mL/30 mL) to give ethyl 4-bromo-lH-pynOlo[2,3-b]pyridine-2- carboxylate (3.2 g, average yield: 61%) as an off-white solid. NMR (400 MHz, DMSO-rfc) d 1.36 (3H, t, J= 7.2 Hz), 4.37 (2H, q, J= 12 Hz), 7.06 (1H, s), 7.48 (1H, d, J= 5.2 Hz), 8.29 (1H, d, J= 4.8 Hz), 12.96 (1H, br s).

References: [1]Journal of Medicinal Chemistry,2010,vol. 53,p. 3973 - 4001.
[2]Patent: WO2008/49855,2008,A2 .Location in patent: Page/Page column 54.
[3]Bioorganic and Medicinal Chemistry Letters,2008,vol. 18,p. 4610 - 4614.
[4]Patent: US2009/18156,2009,A1 .Location in patent: Page/Page column 18-19.
[5]Patent: WO2007/76423,2007,A2 .Location in patent: Page/Page column 96.
[6]Patent: WO2019/126733,2019,A1 .Location in patent: Paragraph 0566-0567.

3
[ 942920-55-0 ]
[ 100-01-6 ]
[ 1021950-41-3 ]

Yield	Reaction Conditions	Operation in experiment
	With potassium tert-butylate;(1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; In N,N-dimethyl-formamide; at 120℃; for 0.5h;Microwave irradiation;	Step B: Ethyl 4-[(4-nitrophenyl)aminol-1/-/-pyrrolof2,3-ipyridine-2-carboxylate; To a suspention of ethyl 4-bromo-1 /-/-pyrrolo[2,3-]pyridine-2-carboxylate (Step A) (538.2 mg, 2 mmol), potassium tert-butoxide (448.8 mg, 4 mmol), 4-nitroaniline (commercially available, for example, from Sigma-Aldrich) (828.8 mg, 6 mmol), and EPO <DP n="56"/>lambda/,lambda/-dimethylformamide (18 ml_) in a microwave vial was added Pd(dppf)CI2 (326.6 mg, 0.4 mmol). After capping, the mixture was heated with Creator at 120 0C for 30 min. The reaction mixture was quenched by saturated aqueous ammonium chloride, and extracted with dichloromethane (20 ml_, 3 times). The organic layer was washed with brine, dried over sodium sulfate, and then evaporated to dryness under reduced pressure. The residue was used for the next step without further purification.

References: [1]Patent: WO2008/49855,2008,A2 .Location in patent: Page/Page column 54-55.

4
[ 942920-55-0 ]
[ 945865-22-5 ]
[ 1165839-15-5 ]

Yield	Reaction Conditions	Operation in experiment
	With sodium carbonate;tetrakis(triphenylphosphine) palladium(0); In 1,2-dimethoxyethane; water; at 120℃; for 0.5h;Microwave irradiation;	Ethyl 4-bromo-1H-pyrrolo[2,3-b]pyridine-2-carboxylate (step A in general intermediate 8, 134.6 mg, 0.5 mmol) and 1-ethyl-3-(3-nitrophenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (general intermediate 9, 171.5 mg, 0.5 mmol) were dissolved in DME (4 mL) and aqueous Na2CO3 (2 M, 0.5 mL). The resulting solution and Pd(PPh3)4 (34.7 mg, 0.03 mmol) were added to a microwave vial. After capping, the mixture was heated with Creator at 120 C. for 30 minutes. SCX purification afforded the residue, which was directly used for the next step without further purification.

References: [1]Patent: US2009/18156,2009,A1 .Location in patent: Page/Page column 20.

5
[ 942920-55-0 ]
[ 20277-69-4 ]
potassium vinyltrifluoroborate [ No CAS ]
C₁₄H₁₇NO₄S [ No CAS ]

References: [1]Tetrahedron Letters,2009,vol. 50,p. 1928 - 1933.

6
[ 942920-11-8 ]
[ 942920-55-0 ]
[ 942920-54-9 ]

References: [1]Journal of Medicinal Chemistry,2010,vol. 53,p. 3973 - 4001.

7
[ 942920-55-0 ]
[ 1292317-54-4 ]
ethyl 4-(3-cyano-4-((tetrahydro-2H-pyran-4-yl)oxy)phenyl)-1H-pyrrolo[2,3-b]pyridine-2-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
500 mg	With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; sodium carbonate; In 1,2-dimethoxyethane; water; at 140℃; for 1h;	To a mixture ethyl 4-bromo-1 H-pyrrolo[2,3-b]pyridine-2-carboxylate (500 mgs, 1.86 mmol) and 2-((tetrahydro-2H-pyran-4-yl)oxy)-5-(4,4,5,5-tetramethyl- 1 ,3,2-dioxaborolan-2-yl)benzonitrile (673 mgs, 2.0 mmol) in DME (6 mL) was 2.0 M aqueous Na2CO3 (2.0 mL, 4 mmol) and Pd(PPh3)4 (107 mgs, 0.09 mmol). The reaction mixture was heated at 140 C for 1 hr. After cooling to rt, ethyl acetate (10 mL) and water (20 mL) was added and the solids were filtered and washed with water and dried to give ethyl 4-(3-cyano-4-((tetrahydro-2H-pyran-4-yl)oxy)phenyl)-1 H-pyrrolo[2,3- b]pyridine-2-carboxylate (500 mgs) LCMS-ESI+ (m/z): [M+H]+ calcd for C22H21 N3O4 as (M+H)+ 392.4 found: 392.1

References: [1]Patent: WO2015/187684,2015,A1 .Location in patent: Page/Page column 122.

8
[ 942920-55-0 ]
2'-(bis(4-methoxybenzyl)amino)-N,N-dimethyl-5'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[2,3'-bipyridine]-5-carboxamide [ No CAS ]
ethyl 4-(2'-(bis(4-methoxybenzyl)amino)-5-(dimethylcarbamoyl)-[2,3'-bipyridin]-5'-yl)-1H-pyrrolo[2,3-b]pyridine-2-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
36.1%	With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; sodium carbonate; In 1,4-dioxane; water; at 90℃; for 16h;Inert atmosphere;	A solution of 2'-(bis(4-methoxybenzyl)amino)-N,N-dimethyl-5'-(4, 4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-[2,3'-bipyridine]-5-carboxamide (3.00 g, 4.93 mmol) in dioxane (15 mL) and H2O (5 mL) was added ethyl 4-bromo-lH-pyrrolo[2,3-b]pyridine-2- carboxylate (1.00 g, 3.72 mmol), Pd(dppf)Cl2 (0.271 g, 0.371 mmol) and Na2C03 (1.18 g, 11.2 mmol). The mixture was stirred at 90 C under N2 atmosphere for 16 h. A black suspension was formed. LCMS showed the purity of desired product (Rt = 0.709 min; MS Calc?d: 670.8; MS Found: 671.3 [M+H]+). The mixture was added sat.NFUCl (40 mL), extracted with EtOAc (40 mL x3). The combined layer was washed with brine (30 mL), dried over Na2SCri and concentrate. The residue was purified by Combi Flash (EtOAc in PE from 0 to 100%) to give ethyl 4-(2'-(bis(4-methoxybenzyl)amino)-5-(dimethylcarbamoyl)-[2,3'-bipyridin]-5'-yl)-lH- pyrrolo[2,3-b]pyridine-2-carboxylate (0.9 g, yield: 36.1%) as a brown solid. NMR (400 MHz, CDCb) d 1.44 (3H, t, J= 7.2 Hz), 3.03 (3H, s), 3.15 (3H, s), 3.80 (6H, s), 4.15 (4H, s), 4.46 (2H, q, J= 7.2 Hz), 6.83 (4H, d , J= 8.4 Hz), 7.06 (4H, d, J= 8.4 Hz), 7.28 (1H, d, J= 4.8 Hz), 7.47 (1H, s), 7.75-7.81 (2H, m), 8.21 (1H, d , J= 2.4 Hz), 8.55 (1H, d , J= 4.8 Hz), 8.75- 8.78 (2H, m), 10.13 (1H, br s).

References: [1]Patent: WO2019/126733,2019,A1 .Location in patent: Paragraph 0575.

9
[ 942920-55-0 ]
4-(2'-amino-5-(dimethylcarbamoyl)-[2,3'-bipyridin]-5'-yl)-N,N-dimethyl-1H-pyrrolo[2,3-b]pyridine-2-carboxamide [ No CAS ]